Company Profile
Ivy Brain Tumor Center
Company Overview
The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, AZ, is a nonprofit tertiary care and translational research program that employs bold, early-phase clinical trial strategies to identify new treatments for aggressive brain tumors, including glioblastoma. Our leading experts in neurosurgical oncology, neuro-oncology, radiation oncology, neuroradiology, neuropathology and neuroscience nursing treat more patients annually than any other brain tumor center in the United States. The Ivy Center’s Phase 0 clinical trials program is the largest in the world and enables personalized care in a fraction of the time and cost associated with traditional drug development. In addition, unlike conventional clinical trials focusing on single drugs, the Ivy Center’s accelerated program tests therapeutic combinations matched to individual patients. We leave no stone unturned in the pursuit of hope and healing. Learn more at IvyBrainTumorCenter.org.
Company History
The Ivy Brain Tumor Center at the Barrow Neurological Institute is a nonprofit translational science initiative established by a $50 million investment in 2018 from the Ben & Catherine Ivy Foundation in partnership with the Barrow Neurological Foundation. This represents the largest single research grant in the history of brain tumor research worldwide. Our research program is singularly focused on discovering new therapies for brain tumor patients through a broad portfolio of pharmacodynamic- and pharmacokinetic-driven clinical trials, combining industry-partnered drug development with the nation’s largest operative brain tumor volume.
Our multidisciplinary team of brain tumor specialists and scientists is accelerating drug discovery and precision medicine in neuro-oncology in an effort to identify the most promising first-in-class therapies for brain tumor patients. The Ivy Brain Tumor Center’s central strategy is to introduce patients to these novel treatment paradigms, identify combined-agent strategies that sidestep brain tumor resistance mechanisms, and validate the utility of promising new regimens using randomized controlled clinical trials. Taken together, our innovative efforts in clinical trial design, an expansive roster of new experimental agents, and access to the nation’s largest brain tumor patient population positions the Ivy Brain Tumor Center to redefine drug development for patients with brain tumors.